科前生物
(688526)
| 流通市值：68.89亿 | | | 总市值：68.89亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 227,536,944.76 | 949,742,023.06 | 737,863,251.81 | 487,290,650.57 |
| 营业收入 | 227,536,944.76 | 949,742,023.06 | 737,863,251.81 | 487,290,650.57 |
| 二、营业总成本 | 135,315,536.88 | 524,371,080.48 | 401,181,258.98 | 257,541,676.39 |
| 营业成本 | 81,909,523.78 | 313,671,966.29 | 243,795,691.84 | 159,428,789.3 |
| 税金及附加 | 3,344,201.3 | 6,399,678.69 | 4,947,850.1 | 3,226,287.12 |
| 销售费用 | 22,245,513.12 | 105,203,660.83 | 81,234,910.86 | 51,325,590.19 |
| 管理费用 | 13,429,405.56 | 59,837,555.5 | 43,466,248.18 | 29,219,952.79 |
| 研发费用 | 25,104,400 | 96,411,370.73 | 71,872,613.35 | 45,497,479.23 |
| 财务费用 | -10,717,506.88 | -57,153,151.56 | -44,136,055.35 | -31,156,422.24 |
| 其中:利息费用 | 72,173.84 | -1,773,682.84 | 269,451.82 | 147,328.99 |
| 其中:利息收入 | 10,229,925.76 | 56,421,355.48 | 45,438,279.37 | 31,413,860.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,366,175.01 | 33,271,389.35 | 27,620,436.69 | 13,267,119.68 |
| 加:投资收益 | 2,145,490.3 | 7,405,727.22 | -9,564,186.97 | 3,572,559.49 |
| 资产处置收益 | - | - | - | 0 |
| 资产减值损失(新) | -6,310,502.25 | -12,636,565.86 | -7,925,846.66 | -671,363.37 |
| 信用减值损失(新) | -7,316,880.5 | 9,693,386.86 | 28,550,162.64 | 885,962.71 |
| 其他收益 | 7,096,490.51 | 20,009,419.46 | 14,949,832.51 | 6,939,358.55 |
| 四、营业利润 | 90,202,180.95 | 483,114,299.61 | 390,312,391.04 | 253,742,611.24 |
| 加:营业外收入 | 29,913.45 | 222,656 | 136,511.44 | 97,257.97 |
| 减:营业外支出 | 127,104.18 | 1,796,169.34 | 1,477,570.85 | 264,961.24 |
| 五、利润总额 | 90,104,990.22 | 481,540,786.27 | 388,971,331.63 | 253,574,907.97 |
| 减:所得税费用 | 11,415,862.54 | 64,599,520.14 | 52,366,559.79 | 34,297,146.77 |
| 六、净利润 | 78,689,127.68 | 416,941,266.13 | 336,604,771.84 | 219,277,761.2 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 78,689,127.68 | 416,941,266.13 | 336,604,771.84 | 219,277,761.2 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 79,236,163.81 | 418,723,155.8 | 337,791,776.24 | 219,896,297.5 |
| 少数股东损益 | -547,036.13 | -1,781,889.67 | -1,187,004.4 | -618,536.3 |
| 扣除非经常损益后的净利润 | 69,451,904.82 | 351,633,712.49 | 274,582,316.3 | 189,959,243.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.9 | 0.72 | 0.47 |
| (二)稀释每股收益 | 0.17 | 0.9 | 0.72 | 0.47 |
| 八、其他综合收益 | -7,104,812.04 | 81,279,244.34 | 47,672,522.15 | 50,736,402.83 |
| 归属于母公司股东的其他综合收益 | -7,104,812.04 | 81,279,244.34 | 47,672,522.15 | 50,736,402.83 |
| 九、综合收益总额 | 71,584,315.64 | 498,220,510.47 | 384,277,293.99 | 270,014,164.03 |
| 归属于母公司股东的综合收益总额 | 72,131,351.77 | 500,002,400.14 | 385,464,298.39 | 270,632,700.33 |
| 归属于少数股东的综合收益总额 | -547,036.13 | -1,781,889.67 | -1,187,004.4 | -618,536.3 |
| 公告日期 | 2026-04-30 | 2026-04-08 | 2025-10-30 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |